Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)
dc.contributor.author | Donovan, Heidi S. | |
dc.contributor.author | Sereika, Susan M. | |
dc.contributor.author | Wenzel, Lari B. | |
dc.contributor.author | Edwards, Robert P. | |
dc.contributor.author | Knapp, Judith E. | |
dc.contributor.author | Hughes, Susan H. | |
dc.contributor.author | Roberge, Mary C. | |
dc.contributor.author | Thomas, Teresa H. | |
dc.contributor.author | Klein, Sara Jo | |
dc.contributor.author | Spring, Michael B. | |
dc.contributor.author | Nolte, Susan | |
dc.contributor.author | Landrum, Lisa M. | |
dc.contributor.author | Casey, A. Catherine | |
dc.contributor.author | Mutch, David G. | |
dc.contributor.author | DeBernardo, Robert L. | |
dc.contributor.author | Muller, Carolyn Y. | |
dc.contributor.author | Sullivan, Stephanie A. | |
dc.contributor.author | Ward, Sandra E. | |
dc.contributor.department | Obstetrics and Gynecology, School of Medicine | |
dc.date.accessioned | 2025-01-21T11:07:47Z | |
dc.date.available | 2025-01-21T11:07:47Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Purpose: GOG-259 was a 3-arm randomized controlled trial of two web-based symptom management interventions for patients with recurrent ovarian cancer. Primary aims were to compare the efficacy of the nurse-guided (Nurse-WRITE) and self-directed (SD-WRITE) interventions to Enhanced Usual Care (EUC) in improving symptoms (burden and controllability) and quality of life (QOL). Methods: Patients with recurrent or persistent ovarian, fallopian, or primary peritoneal cancer with 3+ symptoms were eligible for the study. Participants completed baseline (BL) surveys (symptom burden and controllability and QOL) before random assignment. WRITE interventions lasted 8 weeks to develop symptom management plans for three target symptoms. All women received EUC: monthly online symptom assessment with provider reports; online resources; and every 2-week e-mails. Outcomes were evaluated at 8 and 12 weeks after BL. Repeated-measures modeling with linear contrasts evaluated group by time effects on symptom burden, controllability, and QOL, controlling for key covariates. Results: Participants (N = 497) reported mean age of 59.3 ± 9.2 years. At BL, 84% were receiving chemotherapy and reported a mean of 14.2 ± 4.9 concurrent symptoms, most commonly fatigue, constipation, and peripheral neuropathy. Symptom burden and QOL improved significantly over time (P < .001) for all three groups. A group by time interaction (P < .001) for symptom controllability was noted whereby both WRITE intervention groups had similar improvements from BL to 8 and 12 weeks, whereas EUC did not improve over time. Conclusion: Both WRITE Intervention groups showed significantly greater improvements in symptom controllability from BL to 8 and BL to 12 weeks compared with EUC. There were no significant differences between Nurse-WRITE and SD-WRITE. SD-WRITE has potential as a scalable intervention for a future implementation study. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Donovan HS, Sereika SM, Wenzel LB, et al. Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259). J Clin Oncol. 2022;40(13):1464-1473. doi:10.1200/JCO.21.00656 | |
dc.identifier.uri | https://hdl.handle.net/1805/45306 | |
dc.language.iso | en_US | |
dc.publisher | American Society of Clinical Oncology | |
dc.relation.isversionof | 10.1200/JCO.21.00656 | |
dc.relation.journal | Journal of Clinical Oncology | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Ovarian epithelial carcinoma | |
dc.subject | Fatigue | |
dc.subject | Ovarian neoplasms | |
dc.subject | Palliative care | |
dc.subject | Quality of life | |
dc.subject | Symptom assessment | |
dc.title | Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259) | |
dc.type | Article | |
ul.alternative.fulltext | https://pmc.ncbi.nlm.nih.gov/articles/PMC9061156/ |